<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05111418</url>
  </required_header>
  <id_info>
    <org_study_id>3812</org_study_id>
    <nct_id>NCT05111418</nct_id>
  </id_info>
  <brief_title>Myocardial Bridge Evaluation Towards Personalised Medicine: the RIALTO Registry</brief_title>
  <acronym>RIALTO</acronym>
  <official_title>Myocardial Bridge Evaluation Towards Personalised Medicine: the RIALTO Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myocardial bridge (MB) is a congenital anomaly of epicardial circulation characterized by an&#xD;
      intramural course of a coronary segment. This anatomical arrangement causes the artery to be&#xD;
      squeezed during systole potentially causing flow impairment and ischemia. For this study, MB&#xD;
      is defined as the presence of systolic compression in an epicardial vessel causing at least&#xD;
      50% of caliber reduction from diastole. MB can be disabling as it worsens the quality of&#xD;
      life. Early detection of this congenital condition is crucial, and an invasive functional&#xD;
      assessment of the ischemic burden should be considered to evaluate the need for medical or&#xD;
      surgical therapy.&#xD;
&#xD;
      This is an observational study, involving four Italian centres. Study Objectives are: To&#xD;
      assess the risk of future cardiovascular complications in patients with MB referred for&#xD;
      coronary angiography and the role of beta-blocker therapy; To describe the clinical and&#xD;
      anatomical characteristics of patients presenting with MB; To determine the impact of&#xD;
      cardiovascular medications on symptoms in patients with MB; To describe the anatomical and&#xD;
      clinical features associated with the invasive evidence of ischemia in patients with MB; To&#xD;
      assess the relation between invasively documented ischemia and clinical manifestations in&#xD;
      patients with the MB. Inclusion Criteria: patients referred to undergo ICA (for both elective&#xD;
      or urgent indications) for suspected coronary artery disease found to have an MB with or&#xD;
      without other epicardial lesions amenable to revascularization; Age above 18 y.o.; Ability to&#xD;
      provide Informed Consent. Exclusion Criteria are Patients with life expectancy below 12&#xD;
      months and Patients with severe valvular heart disease. The primary endpoint is the incidence&#xD;
      of MACE defined as the composite of cardiac death, myocardial infarction, cardiac&#xD;
      hospitalization, and target vessel revascularization. The secondary endpoint is evaluating&#xD;
      the Rate of patients with SAQ &lt; 70 and the Rate of patients with &quot;high-risk features&quot; on CT&#xD;
      scan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">March 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 17, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Incidence of MACE</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of MACE defined as the composite of cardiac death, myocardial infarction, cardiac hospitalization and target vessel revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with SAQ &lt; 70</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with &quot;high risk features&quot; on CT scan</measure>
    <time_frame>12 months</time_frame>
    <description>High risk features</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Myocardial Bridge</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Population with suspected coronary artery disease found to have a myocardial bridge with or&#xD;
        without other epicardial lesions amenable to revascularization&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients referred to undergo ICA (for both elective or urgent indications) for&#xD;
             suspected coronary artery disease found to have a myocardial bridge with or without&#xD;
             other epicardial lesions amenable to revascularization&#xD;
&#xD;
          -  Age above 18 y.o.&#xD;
&#xD;
          -  Ability to provide Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with life expectancy below 12 months&#xD;
&#xD;
          -  Patients with severe valvular heart disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Domenico D'Amario</last_name>
    <phone>063015</phone>
    <phone_ext>4187</phone_ext>
    <email>domenico.damario@policlinicogemelli.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arcispedale S. Anna, Azienda Ospedaliero - Universitaria di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <state>Italia</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo Tebaldi</last_name>
      <email>tblmtt@unife.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Martino IRCCS, Universit√† di Genova</name>
      <address>
        <city>Genova</city>
        <state>Italia</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Pescetelli</last_name>
      <email>fabiopescetelli91@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino IRCCS</name>
      <address>
        <city>Milano</city>
        <state>Italia</state>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francescca Triani</last_name>
      <email>francesca.triani@cardiologicomonzino.it</email>
    </contact>
    <contact_backup>
      <last_name>Francesca Triani</last_name>
      <email>francesca.triani@cardiologicomonzino.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</name>
      <address>
        <city>Roma</city>
        <state>Italia</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domenico D'Amario</last_name>
      <phone>063015</phone>
      <phone_ext>4187</phone_ext>
      <email>domenico.damario@policlinicogemelli.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</investigator_affiliation>
    <investigator_full_name>DAMARIO DOMENICO</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Myocardial Bridge</keyword>
  <keyword>MACE</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Beta-blockers</keyword>
  <keyword>Coronary angiography</keyword>
  <keyword>Personalised medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Bridging</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

